Related Experiment Video
Updated: Nov 15, 2025

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
Temporal trends in heart failure medication prescription in a population-based cohort study
Alicia Uijl1,2,3,4, Ilonca Vaartjes5, S Denaxas3,4,6,7
1Julius Global Health, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands a.uijl@umcutrecht.nl.
Insights
Heart failure (HF) medication patterns show increased beta-blocker use but stagnant mineralocorticoid receptor-antagonist prescriptions. Few changes in HF drug management occurred within six months of diagnosis.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Heart failure (HF) management relies on timely pharmacological intervention.
- Understanding temporal prescription trends is crucial for optimizing patient care and outcomes.
Purpose of the Study:
- To analyze the trends in heart failure (HF) medication prescriptions over a 13-year period in the UK.
- To identify patterns in the pharmacological management of HF in a real-world patient cohort.
Main Methods:
- Utilized electronic health records (EHR) from primary and secondary care in the UK.
- Identified 85,732 patients diagnosed with HF between 2002 and 2015.
- Examined prescription patterns for key HF medications over time and by patient demographics.
Main Results:
- Beta-blocker prescriptions increased significantly from 29% to 54% between 2002-2005 and 2013-2015.
- Mineralocorticoid receptor-antagonist (MR-antagonist) prescriptions remained low and unchanged (18%) throughout the study period.
- Women and elderly patients showed lower prescription rates for several key HF medications, and patients without primary care follow-up had reduced prescription rates.
Conclusions:
- Despite increased beta-blocker use, MR-antagonist utilization for HF remains suboptimal and static.
- Pharmacological management of HF shows limited changes within the initial six months post-diagnosis.
- Real-world data highlights disparities in HF medication prescribing, particularly for women and the elderly.
Objective:
We examined temporal heart failure (HF) prescription patterns in a large representative sample of real-world patients in the UK, using electronic health records (EHR).
Methods:
From primary and secondary care EHR, we identified 85 732 patients with a HF diagnosis between 2002 and 2015. Almost 50% of patients with HF were women and the median age was 79.1 (IQR 70.2-85.7) years, with age at diagnosis increasing over time.
Results:
We found several trends in pharmacological HF management, including increased beta blocker prescriptions over time (29% in 2002-2005 and 54% in 2013-2015), which was not observed for mineralocorticoid receptor-antagonists (MR-antagonists) (18% in 2002-2005 and 18% in 2013-2015); higher prescription rates of loop diuretics in women and elderly patients together with lower prescription rates of angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers, beta blockers or MR-antagonists in these patients; little change in medication prescription rates occurred after 6 months of HF diagnosis and, finally, patients hospitalised for HF who had no recorded follow-up in primary care had considerably lower prescription rates compared with patients with a HF diagnosis in primary care with or without HF hospitalisation.
Conclusion:
In the general population, the use of MR-antagonists for HF remained low and did not change throughout 13 years of follow-up. For most patients, few changes were seen in pharmacological management of HF in the 6 months following diagnosis.
Related Concept Videos
Heart Failure V: Medical Management
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure Drugs: β-Blockers
Heart Failure I: Introduction
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Drug Dosing: Geriatric Patients
